Matinas BioPharma Holdings, Inc.
MTNB · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $85 | $2,376 |
| Gross Profit | $0 | $0 | -$85 | -$2,376 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $85 | $2,376 |
| G&A Expenses | $1,577 | $1,837 | $1,861 | $1,662 |
| SG&A Expenses | $1,577 | $1,837 | $1,861 | $1,662 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$85 | $2,055 |
| Operating Expenses | $1,577 | $1,837 | $1,861 | $6,093 |
| Operating Income | -$1,577 | -$1,837 | -$1,946 | -$8,469 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$573 | -$3,408 | $290 | -$44 |
| Pre-Tax Income | -$2,150 | -$5,245 | -$1,656 | -$8,513 |
| Tax Expense | $0 | $0 | $0 | -$80 |
| Net Income | -$2,150 | -$5,245 | -$1,656 | -$8,433 |
| % Margin | – | – | – | – |
| EPS | -0.4 | -1.03 | -0.33 | -1.73 |
| % Growth | 61.2% | -212.1% | 80.9% | – |
| EPS Diluted | -0.4 | -1.03 | -0.33 | -1.73 |
| Weighted Avg Shares Out | 5,436 | 5,087 | 5,087 | 4,866 |
| Weighted Avg Shares Out Dil | 5,436 | 5,087 | 5,087 | 4,866 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $111 | $13 | $19 | $91 |
| EBITDA | -$2,039 | -$1,824 | -$1,927 | -$3,947 |
| % Margin | – | – | – | – |